DK0796341T3 - Identifikation af gener, som tillader tilpasning af en mikroorganisme til en særlig omgivelse - Google Patents
Identifikation af gener, som tillader tilpasning af en mikroorganisme til en særlig omgivelseInfo
- Publication number
- DK0796341T3 DK0796341T3 DK95939362T DK95939362T DK0796341T3 DK 0796341 T3 DK0796341 T3 DK 0796341T3 DK 95939362 T DK95939362 T DK 95939362T DK 95939362 T DK95939362 T DK 95939362T DK 0796341 T3 DK0796341 T3 DK 0796341T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleic acid
- microorganism
- microorganisms
- mutant
- environment
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title abstract 7
- 230000006978 adaptation Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000003550 marker Substances 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 230000002779 inactivation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9424921.6A GB9424921D0 (en) | 1994-12-09 | 1994-12-09 | Identification of genes |
GBGB9501881.8A GB9501881D0 (en) | 1995-01-31 | 1995-01-31 | Identification of genes |
GBGB9509239.1A GB9509239D0 (en) | 1995-05-05 | 1995-05-05 | Identification of genes |
PCT/GB1995/002875 WO1996017951A2 (en) | 1994-12-09 | 1995-12-11 | Identification of genes responsible for in vivo survival of microorganisms |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0796341T3 true DK0796341T3 (da) | 1999-06-14 |
Family
ID=27267507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95939362T DK0796341T3 (da) | 1994-12-09 | 1995-12-11 | Identifikation af gener, som tillader tilpasning af en mikroorganisme til en særlig omgivelse |
DK98201907T DK0889120T3 (da) | 1994-12-09 | 1995-12-11 | Virulensgener i VGC2-regionen af Salmonella |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98201907T DK0889120T3 (da) | 1994-12-09 | 1995-12-11 | Virulensgener i VGC2-regionen af Salmonella |
Country Status (21)
Country | Link |
---|---|
US (7) | US5876931A (da) |
EP (3) | EP0889120B1 (da) |
JP (3) | JP3522285B2 (da) |
KR (4) | KR100445103B1 (da) |
CN (3) | CN1160469C (da) |
AT (2) | ATE171477T1 (da) |
AU (1) | AU711524C (da) |
CA (2) | CA2623339C (da) |
CZ (1) | CZ296981B6 (da) |
DE (3) | DE69505011T2 (da) |
DK (2) | DK0796341T3 (da) |
ES (2) | ES2126332T3 (da) |
FI (1) | FI121601B (da) |
HK (2) | HK1009833A1 (da) |
HU (1) | HUT76975A (da) |
NO (2) | NO320492B1 (da) |
NZ (3) | NZ502020A (da) |
PT (1) | PT889120E (da) |
RU (1) | RU2370541C2 (da) |
SG (4) | SG56084A1 (da) |
WO (1) | WO1996017951A2 (da) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100445103B1 (ko) * | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
AU743007B2 (en) * | 1996-06-17 | 2002-01-17 | Essential Therapeutics, Inc. | Screening methods using microbial strain pools |
US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
NO974299D0 (no) * | 1997-09-18 | 1997-09-18 | Forskningsparken I Aas As | Metode for stabil merking av mikroorganismer |
EP0943681A1 (en) * | 1998-01-22 | 1999-09-22 | Vrije Universiteit Brussel | Live attenuated salmonella vaccine |
AU2144499A (en) * | 1998-01-22 | 1999-08-09 | Vrije Universiteit Brussel | Live attenuated salmonella vaccine |
WO1999045136A1 (en) * | 1998-03-05 | 1999-09-10 | University Of British Columbia | Methods for assaying type iii secretion inhibitors |
CA2323633A1 (en) * | 1998-03-18 | 1999-09-23 | Quark Biotech, Inc. | Selection subtraction approach to gene identification |
WO1999059630A1 (en) * | 1998-05-15 | 1999-11-25 | University Of California Los Angeles | Type iii bordetella secretion system |
ATE486940T1 (de) | 1998-09-04 | 2010-11-15 | Emergent Product Dev Uk Ltd | Abgeschwächte salmonella sp12 mutante als antigen-träger. |
AU6504399A (en) * | 1998-09-30 | 2000-04-17 | Boston Medical Center Corporation | Identification of virulence determinant activators in prokaryotic pathogens government support |
US6720139B1 (en) | 1999-01-27 | 2004-04-13 | Elitra Pharmaceuticals, Inc. | Genes identified as required for proliferation in Escherichia coli |
US6299850B1 (en) | 1999-03-16 | 2001-10-09 | The United States Of America As Represented By The Department Of Energy | Carbon activation process for increased surface accessibility in electrochemical capacitors |
ES2535961T3 (es) * | 1999-04-09 | 2015-05-19 | Zoetis P&U Llc | Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia |
US6790950B2 (en) | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
GB9910812D0 (en) * | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
AU5559300A (en) * | 1999-07-06 | 2001-01-22 | Institut Pasteur | Method of making and identifying attenuated microorganisms, compositions utilizing the sequences responsible for attenuation, and preparations containing attenuated microorganisms |
WO2001034810A2 (en) * | 1999-11-09 | 2001-05-17 | Elitra Pharmaceuticals, Inc. | Genes essential for microbial proliferation |
WO2001057075A2 (en) * | 2000-02-03 | 2001-08-09 | Microscience Limited | Virulence genes, proteins, and their use |
US6783985B1 (en) | 2000-02-18 | 2004-08-31 | Elitra Pharmaceuticals Inc. | Gene disruption methodologies for drug target discovery |
BR0109322A (pt) | 2000-03-17 | 2002-12-10 | Upjohn Co | Materiais e métodos de vacina de salmonella |
GB0008748D0 (en) * | 2000-04-11 | 2000-05-31 | Univ Manchester | Mutant bank |
GB0011108D0 (en) * | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
US20020076722A1 (en) * | 2000-09-13 | 2002-06-20 | Neyfakh Alexander A. | Antibiotic hypersusceptibility mutations in bacteria |
WO2002053732A2 (en) * | 2000-12-28 | 2002-07-11 | Pangenex | Methods for making polynucleotide libraries, polynucleotide arrays, and cell librraries for high-throughput genomics analysis |
US20030180953A1 (en) * | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
EP1390468A4 (en) * | 2001-04-23 | 2004-09-22 | Elitra Pharmaceuticals Inc | IDENTIFICATION OF ESSENTIAL GENES OF ASPERGILLUS FUMIGATUS AND METHOD OF USE |
ATE345386T1 (de) * | 2001-05-17 | 2006-12-15 | Creatogen Ag | Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben |
CA2450658A1 (en) * | 2001-06-15 | 2002-12-27 | Chiron Corporation | Essential and important genes of pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents |
WO2003089572A2 (en) * | 2002-04-15 | 2003-10-30 | Chiron Corporation | Essential and important genes of pseudomonas aeroginosa and the use thereof to design or identify antibacterial agents |
WO2003000721A2 (en) | 2001-06-22 | 2003-01-03 | Health Protection Agency | Mycobacterial antigens expressed under low oxygen tension |
WO2003004520A2 (en) | 2001-07-04 | 2003-01-16 | Health Protection Agency | Mycobacterial antigens expressed during latency |
WO2003008631A2 (en) * | 2001-07-20 | 2003-01-30 | Health Protection Agency | Tagging of microorganisms |
US7026123B1 (en) * | 2001-08-29 | 2006-04-11 | Pioneer Hi-Bred International, Inc. | UTR tag assay for gene function discovery |
GB0125535D0 (en) | 2001-10-24 | 2001-12-12 | Microbiological Res Authority | Mycobacterial genes down-regulated during latency |
US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
US20050019335A1 (en) * | 2001-11-12 | 2005-01-27 | Lowery David E | Salmonella vaccine |
US20030170694A1 (en) * | 2001-12-21 | 2003-09-11 | Daniel Wall | Stabilized nucleic acids in gene and drug discovery and methods of use |
US7449178B2 (en) | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
DE60230717D1 (de) * | 2002-04-05 | 2009-02-26 | Merial Sas | Attenuirte Gram-negative Bakterien |
EP1534325A4 (en) * | 2002-08-20 | 2007-10-17 | Novartis Vaccines & Diagnostic | INSERTION OF RANDOM TRANSPOSONS IN STAPHYLOCOCCUS AND USE TO IDENTIFY ESSENTIAL GENES |
FI116068B (fi) * | 2003-09-15 | 2005-09-15 | Fit Biotech Oyj Plc | Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi |
ATE438681T1 (de) * | 2003-11-21 | 2009-08-15 | Merck Patent Gmbh | Verfahren zur modifikation von chiralen flüssigkristallfilmen mit hilfe von extraktionsmitteln |
US20050266447A1 (en) * | 2004-04-19 | 2005-12-01 | Pioneer Hi-Bred International, Inc. | Method for identifying activators of gene transcription |
WO2006085899A2 (en) | 2004-05-21 | 2006-08-17 | The Regents Of The University Of California | Method for enhancing production of isoprenoid compounds |
CN105950667A (zh) | 2005-07-05 | 2016-09-21 | 加利福尼亚大学董事会 | 编码类异戊烯修饰酶的多核苷酸和其使用方法 |
EP1752532A1 (en) * | 2005-08-09 | 2007-02-14 | Helmholtz-Zentrum für Infektionsforschung GmbH | Extracellular polyhydroxyalkanoates produced by genetically engineered microorganisms |
US7659097B2 (en) | 2006-05-26 | 2010-02-09 | Amyris Biotechnologies, Inc. | Production of isoprenoids |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
DK3020799T3 (da) | 2006-09-26 | 2020-09-21 | Amyris Biotechnologies Inc | Fremstilling af isoprenoider og isoprenoid-prækursorer |
WO2008153772A2 (en) * | 2007-05-25 | 2008-12-18 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
US8703153B2 (en) | 2008-06-16 | 2014-04-22 | Prokarium Ltd. | Salmonella vectored vaccines against Chlamydia and methods of use |
US8383345B2 (en) | 2008-09-12 | 2013-02-26 | University Of Washington | Sequence tag directed subassembly of short sequencing reads into long sequencing reads |
US9051665B2 (en) * | 2008-11-20 | 2015-06-09 | Steven L. Zeichner | Method for screening biomolecules |
US10369772B2 (en) | 2012-07-10 | 2019-08-06 | Textron Innovations Inc. | Method of making core-stiffened structure |
US8715962B2 (en) | 2010-03-31 | 2014-05-06 | Codexis, Inc. | Production of geranyl diphosphate |
DK2569425T3 (da) | 2010-05-10 | 2016-10-03 | Univ California | Endoribonuklease-sammensætninger og fremgangsmåder til anvendelse deraf |
US8829171B2 (en) | 2011-02-10 | 2014-09-09 | Illumina, Inc. | Linking sequence reads using paired code tags |
US9074251B2 (en) | 2011-02-10 | 2015-07-07 | Illumina, Inc. | Linking sequence reads using paired code tags |
AU2012212148B8 (en) | 2011-02-02 | 2017-07-06 | University Of Washington Through Its Center For Commercialization | Massively parallel contiguity mapping |
US8481052B2 (en) * | 2011-05-17 | 2013-07-09 | Cj Cheiljedang Corporation | Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same |
CN104093833B (zh) | 2011-12-16 | 2017-11-07 | 斯坦福大学托管董事会 | 视蛋白多肽及其使用方法 |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
SI2885010T1 (sl) | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
AU2013334229B2 (en) | 2012-10-25 | 2018-02-15 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
US9683230B2 (en) | 2013-01-09 | 2017-06-20 | Illumina Cambridge Limited | Sample preparation on a solid support |
IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
WO2014142850A1 (en) | 2013-03-13 | 2014-09-18 | Illumina, Inc. | Methods and compositions for nucleic acid sequencing |
EP2981610A1 (en) | 2013-04-05 | 2016-02-10 | Université du Luxembourg | Biotechnological production of itaconic acid |
CA2914768A1 (en) | 2013-06-10 | 2014-12-18 | Ipierian, Inc. | Methods of treating a tauopathy |
EP3957750A1 (en) | 2013-12-20 | 2022-02-23 | Illumina, Inc. | Preserving genomic connectivity information in fragmented genomic dna samples |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11873480B2 (en) | 2014-10-17 | 2024-01-16 | Illumina Cambridge Limited | Contiguity preserving transposition |
EP3280440B1 (en) | 2015-04-06 | 2022-11-16 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
BR112018004181A2 (pt) | 2015-09-02 | 2018-09-25 | Immutep S.A.S. | anticorpos anti-lag-3 |
WO2020047527A2 (en) | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
SG11201807286WA (en) | 2016-03-19 | 2018-10-30 | F1 Oncology Inc | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
TN2018000341A1 (en) | 2016-04-04 | 2020-06-15 | Bioverativ Usa Inc | ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF. |
CA3030003A1 (en) | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
BR112019000709A8 (pt) * | 2016-07-13 | 2023-03-21 | Ubiome Inc | Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário |
CA3040253A1 (en) | 2016-10-12 | 2018-04-19 | Bioverativ Usa Inc. | Anti-c1s antibodies and methods of use thereof |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
EP3571229A1 (en) | 2017-01-18 | 2019-11-27 | F1 Oncology, Inc. | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
KR20200003370A (ko) | 2017-03-03 | 2020-01-09 | 에프1 온콜로지, 인코포레이티드 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
AU2018256863B2 (en) | 2017-04-27 | 2024-06-06 | Regents Of The University Of California | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives |
CN111527105A (zh) | 2017-10-11 | 2020-08-11 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
WO2023168305A1 (en) | 2022-03-01 | 2023-09-07 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
LU88258I2 (da) | 1978-12-22 | 1994-02-03 | ||
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US5210035A (en) | 1980-05-19 | 1993-05-11 | Board Of Trustees Of Leland Stanford Jr. University | Non-reventing live vaccines |
US4550081A (en) * | 1980-05-19 | 1985-10-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Non-reverting salmonella |
US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US5397697A (en) * | 1989-01-10 | 1995-03-14 | Ciba-Geigy Corporation | Identification of plant-responsive genes of bacteria |
FR2664614B1 (fr) | 1990-07-11 | 1992-10-16 | Pasteur Institut | Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires. |
SE9101433D0 (sv) | 1991-05-13 | 1991-05-13 | Marianne Hansson | Recombinant dna sequence and its use |
WO1993004202A1 (en) * | 1991-08-22 | 1993-03-04 | Washington University | Polynucleotide probes for salmonella |
WO1993007266A1 (en) * | 1991-10-07 | 1993-04-15 | Idaho Research Foundation, Inc. | Genetic construct for selection of homologous recombinants on a single selective medium |
US5356797A (en) | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
WO1993010246A1 (en) | 1991-11-15 | 1993-05-27 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
CA2148829A1 (en) | 1992-11-06 | 1994-05-26 | Keum Hwa Choi | Avirulent live vaccine and method for immunizing animals against p. multocida pasteurellosis |
WO1994026933A1 (en) * | 1993-05-13 | 1994-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic footprinting: insertional mutagenesis and genetic selection |
US5700638A (en) | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
DE4405652A1 (de) * | 1994-02-22 | 1995-09-07 | Hoechst Ag | Verfahren zur Herstellung von nichtoxidischer Keramik mit definierter Wärmeleitfähigkeit |
WO1996011708A1 (en) | 1994-10-18 | 1996-04-25 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
KR100445103B1 (ko) | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
US5700683A (en) * | 1995-02-17 | 1997-12-23 | Pathogenesis Corporation | Virulence-attenuating genetic deletions deleted from mycobacterium BCG |
US5700928A (en) * | 1995-10-16 | 1997-12-23 | Smithkline Beecham, P.L.C. | Polynucleotide encoding saliva binding protein |
CA2237581A1 (en) | 1995-11-14 | 1997-05-22 | The General Hospital Corporation | Salmonella secreted proteins and uses thereof |
US6030624A (en) | 1996-08-16 | 2000-02-29 | Uab Research Foundation | Mucosal immunogens for novel vaccines |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
WO1998035562A1 (en) | 1997-02-14 | 1998-08-20 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
GB9804809D0 (en) | 1998-03-06 | 1998-04-29 | Wallis Timothy S | Attenuated salmonella:materials and methods relating thereto |
US6585975B1 (en) | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
ATE486940T1 (de) | 1998-09-04 | 2010-11-15 | Emergent Product Dev Uk Ltd | Abgeschwächte salmonella sp12 mutante als antigen-träger. |
AU773003B2 (en) | 1998-11-09 | 2004-05-13 | Microscience Limited | Virulence genes and proteins, and their use |
GB9910812D0 (en) | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
WO2001032697A2 (en) | 1999-11-05 | 2001-05-10 | L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) | Virulence genes and proteins from brucella melitensis, and their use |
WO2001048208A2 (en) | 1999-12-23 | 2001-07-05 | Vmax Limited | Streptococcus pyogenes virulence genes and proteins and their use |
GB0011108D0 (en) | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
US6548368B1 (en) * | 2000-08-23 | 2003-04-15 | Applied Materials, Inc. | Method of forming a MIS capacitor |
GB0127657D0 (en) | 2001-11-19 | 2002-01-09 | Microscience Ltd | Virulence genes and proteins and their use |
US7449178B2 (en) | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
-
1995
- 1995-12-11 KR KR1019970703866A patent/KR100445103B1/ko not_active IP Right Cessation
- 1995-12-11 SG SG9801353A patent/SG56084A1/en unknown
- 1995-12-11 KR KR1020037017326A patent/KR100551104B1/ko not_active IP Right Cessation
- 1995-12-11 AT AT95939362T patent/ATE171477T1/de active
- 1995-12-11 CA CA2623339A patent/CA2623339C/en not_active Expired - Fee Related
- 1995-12-11 EP EP98201907A patent/EP0889120B1/en not_active Expired - Lifetime
- 1995-12-11 NZ NZ502020A patent/NZ502020A/xx not_active IP Right Cessation
- 1995-12-11 DE DE69505011T patent/DE69505011T2/de not_active Expired - Lifetime
- 1995-12-11 ES ES95939362T patent/ES2126332T3/es not_active Expired - Lifetime
- 1995-12-11 KR KR1020057005514A patent/KR20050052665A/ko not_active Application Discontinuation
- 1995-12-11 PT PT98201907T patent/PT889120E/pt unknown
- 1995-12-11 CN CNB951975757A patent/CN1160469C/zh not_active Expired - Fee Related
- 1995-12-11 SG SG200301515A patent/SG119177A1/en unknown
- 1995-12-11 HU HU9701765A patent/HUT76975A/hu not_active Application Discontinuation
- 1995-12-11 DK DK95939362T patent/DK0796341T3/da active
- 1995-12-11 SG SG200607028-8A patent/SG165157A1/en unknown
- 1995-12-11 JP JP51742896A patent/JP3522285B2/ja not_active Expired - Fee Related
- 1995-12-11 KR KR1020067017679A patent/KR20060099543A/ko not_active Application Discontinuation
- 1995-12-11 SG SG2006070270A patent/SG173213A1/en unknown
- 1995-12-11 AT AT98201907T patent/ATE215986T1/de active
- 1995-12-11 CZ CZ0175597A patent/CZ296981B6/cs not_active IP Right Cessation
- 1995-12-11 AU AU41219/96A patent/AU711524C/en not_active Ceased
- 1995-12-11 WO PCT/GB1995/002875 patent/WO1996017951A2/en active IP Right Grant
- 1995-12-11 EP EP01205191A patent/EP1285960A3/en not_active Withdrawn
- 1995-12-11 DE DE0889120T patent/DE889120T1/de active Pending
- 1995-12-11 CN CNA031549489A patent/CN1510137A/zh active Pending
- 1995-12-11 ES ES98201907T patent/ES2178101T3/es not_active Expired - Lifetime
- 1995-12-11 EP EP95939362A patent/EP0796341B1/en not_active Expired - Lifetime
- 1995-12-11 NZ NZ511170A patent/NZ511170A/en not_active IP Right Cessation
- 1995-12-11 CN CN2006101006621A patent/CN1912141B/zh not_active Expired - Fee Related
- 1995-12-11 RU RU2003135645/13A patent/RU2370541C2/ru not_active IP Right Cessation
- 1995-12-11 CA CA002206515A patent/CA2206515C/en not_active Expired - Fee Related
- 1995-12-11 DK DK98201907T patent/DK0889120T3/da active
- 1995-12-11 NZ NZ296581A patent/NZ296581A/en not_active IP Right Cessation
- 1995-12-11 DE DE69526377T patent/DE69526377T2/de not_active Expired - Lifetime
- 1995-12-11 US US08/637,759 patent/US5876931A/en not_active Expired - Lifetime
-
1997
- 1997-05-30 NO NO19972468A patent/NO320492B1/no not_active IP Right Cessation
- 1997-06-06 FI FI972424A patent/FI121601B/fi not_active IP Right Cessation
- 1997-06-09 US US08/871,355 patent/US6015669A/en not_active Expired - Lifetime
-
1998
- 1998-09-15 HK HK98110640A patent/HK1009833A1/xx not_active IP Right Cessation
- 1998-12-01 US US09/201,945 patent/US6342215B1/en not_active Expired - Fee Related
-
2000
- 2000-11-16 US US09/714,602 patent/US6984490B1/en not_active Expired - Fee Related
-
2002
- 2002-08-02 JP JP2002226740A patent/JP4220195B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-01 NO NO20042249A patent/NO327361B1/no not_active IP Right Cessation
- 2004-08-09 HK HK07108847.1A patent/HK1100782A1/xx not_active IP Right Cessation
-
2005
- 2005-08-09 US US11/199,853 patent/US20060216309A1/en not_active Abandoned
-
2007
- 2007-08-17 US US11/840,903 patent/US7842290B2/en not_active Expired - Fee Related
-
2008
- 2008-05-21 JP JP2008133664A patent/JP2009005688A/ja active Pending
-
2010
- 2010-09-27 US US12/890,892 patent/US20110229515A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0796341T3 (da) | Identifikation af gener, som tillader tilpasning af en mikroorganisme til en særlig omgivelse | |
Pattee | Distribution of Tn551 insertion sites responsible for auxotrophy on the Staphylococcus aureus chromosome | |
Attardi | Animal mitochondrial DNA: an extreme example of genetic economy | |
Zhang et al. | Gene isolation through genomic complementation using an indexed library of Chlamydomonas reinhardtii DNA | |
ATE198355T1 (de) | Alpha-amidierende enzymzusammensetzungen und verfahren zu deren herstellung und verwendung | |
DK0805867T3 (da) | DNA integration ved transposition | |
KR930702521A (ko) | 효율적인 유전적 억제요소를 얻는 방법 및 그 용도 | |
ATE365806T1 (de) | L-lysin produzierende coryneforme bakterien und verfahren zur herstellung von lysin | |
DE69938722D1 (de) | Verfahren zur herstellung von heterologen polypeptiden in trichothecene mangelmutanten filamentlösen pilzen | |
AU8515391A (en) | Test to determine an organism's species and/or population identity by direct nucleotide sequence analysis of defined segments of its genome | |
AU3868197A (en) | Yeast vectors and process for producing proteins with the use of the same | |
ATE44766T1 (de) | Verfahren zur vergroesserung der expression eines bestimmten gens im bacillus subtilis und erhaltene staemme. | |
RU2003104785A (ru) | Метод разработки генома, основанный на картировании, для идентификации локусов регуляции уровня генных транскриптов и продуктов | |
AU2049699A (en) | Method of parallel screening for insertion mutants and a kit to perform this method | |
CA2394962A1 (en) | A functional gene array in yeast | |
Holden | Identification of genes | |
CN109628447B (zh) | 特异靶向羊友好位点H11的sgRNA及其编码DNA和应用 | |
Li et al. | piggyBac transposon-based insertional mutagenesis for the fission yeast Schizosaccharomyces pombe | |
Yasukochi et al. | Integration of molecular and classical linkage groups of the silkworm, Bombyx mori (n= 28) | |
Westergaard | Chemical mutagenesis as a tool in macromolecular genetics | |
WO2002027025A3 (en) | Application of bioinformatics for direct study of unculturable microorganisms | |
Ali | The role of genomic DNA and introns in gene transfer | |
CN109536614A (zh) | 猪蛔虫全基因组微卫星分子标记及其引物与应用 | |
CA2100791A1 (en) | Method of Directing Biosynthesis of Specific Polyketides | |
Smith et al. | How many genes does a cell need? |